Pharmaceuticals

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of...

2024-06-06 19:00 1559

NDA for Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Filed in Japan for Treating Alzheimer's Dementia

TOKYO, June 6, 2024 /PRNewswire/ -- Luye Pharma Group announced that its partner Towa Pharmaceutical Co., Ltd. (Towa) has filed a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) inJapan for the Rivastigmine Twice Weekly Transdermal Patch for treating mild to modera...

2024-06-06 17:33 2660

Alphamab Oncology Collaborated with ArriVent in relation to the Research, Development and Commercialization of ADC Products

SUZHOU, China, June 6, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Alphamab"), a wholly-owned subsidiary of the Company, entered into a research and collaboration agreement (the "Collaboration Agreement") with ArriVen...

2024-06-06 10:21 2223

RemeGen Showcases Research Results at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, Highlighting Its Prolific Innovation in Global Cancer Treatment

YANTAI, China, June 5, 2024 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, showcased its innovation in the field of global cancer treatment at the American Society of Clinical Oncology Annu...

2024-06-05 21:42 2531

Sunway Medical Centre retains Malaysia's top spot in Paediatrics, according to latest Newsweek rankings

The hospital is also ranked highly in the areas of Oncology, Neurology, Neurosurgery, Cardiology, and Cardiac Surgery. SUNWAY CITY, Malaysia, June 5, 2024 /PRNewswire/ -- Sunway Medical Centre (SMC), Sunway City, the flagship quaternary hospital under the Sunway Healthcare Group, retained its to...

2024-06-05 20:00 2648

Oricell Presented Long-term Follow-up Data of OriCAR-017 in RRMM at 2024 ASCO Annual Meeting, Highlighting the Sustained Efficacy of GPRC5D CAR-T Therapy

SHANGHAI and ROSELAND, N.J., June 5, 2024 /PRNewswire/ -- Oricell Therapeutics, a pioneering clinical-stage biopharmaceutical company, has presented the two-year long-term follow-up results of OriCAR-017, an open-label Phase I study evaluating GPRC5D-targeted CAR-T therapy in patients with relaps...

2024-06-05 19:59 2097

FDA Approved Phase II/III Clinical Study of KPG-121 in Combination with Abiraterone as a First Line Treatment for mCRPC

HEFEI, China, June 5, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has recently approved a Phase II/III clinical trial of KPG-121 in combination with Abiraterone for a first-line treatment of metastatic castration resistant prost...

2024-06-05 19:00 1762

Pierre Fabre Laboratories Announce IND Filing for PFL-002/VERT-002, a Potential Treatment for Patients with Solid Tumors, Including Non-Small Cell Lung Cancer with MET Alterations

CASTRES, France, June 5, 2024 /PRNewswire/ -- Pierre Fabre Laboratories today announced the filing of an investigational new drug ("IND") application to the U.S. Food and Drug Administration ("FDA") to initiate a first-in-human (FIH) Phase I/II clinical trial with PFL-002/VERT-002 for solid tumor...

2024-06-05 15:15 1999

GC Genome Highlights Promising New Approach for Non-invasive Colorectal Cancer Detection at ASCO 2024

YONGIN, South Korea, June 5, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, presented new data from its AI-based liquid biopsy platform for non-invasive colorectal cancer (CRC) detection at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Conducted...

2024-06-05 14:00 2065

ASG Pioneers Development of novel inhaled drugs and Accelerates R&D Progress

TAIPEI, June 5, 2024 /PRNewswire/ – Asia Scientific Global (ASG), a leader in the research and development of novel inhaled drugs, has set up a laboratory in Taiwan, and plans to establish a second facility in Singapore later this year. This new lab will focus on developing 505(b)2 new dosage form...

2024-06-05 12:30 1688

Live from ASCO 2024 | Oral Report Released Latest Data of Olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%

SUZHOU, China and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated clinical data of olvere...

2024-06-05 11:46 1536

Live from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM

SUZHOU, China, and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated results from a global,...

2024-06-05 11:31 1463

Dalton Pharma Services Invests in Robotic Aseptic Powder Fill-Finish Line from 3P innovation

TORONTO, June 5, 2024 /PRNewswire/ -- Pharmaceutical manufacturing company, Dalton Pharma Services (a Seikagaku Group company), has recently commissioned 3P innovation (Warwick, UK) to design and construct a fully automated state-of-the-art high-speed aseptic powder filling line to expedite the ...

2024-06-05 10:00 1594

CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO

SHANGHAI, June 4, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the final follow-up results of the investigator-initiated trial C...

2024-06-04 20:50 1756

GCBP Sponsors 2024 Spring Symposium for KASBP and Present Research Findings

YONGIN, South Korea, June 4, 2024 /PRNewswire/ -- GC Biopharma announced that it will attend 2024 Spring Symposium of the Korean American Society in Biotech and Pharmaceuticals (KASBP) onJune 7-8th at Waltham, Massachusetts as a sponsor to share keynote presentation, present Korean Scientist Awar...

2024-06-04 13:00 1599

Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety

SUZHOU, China and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest results from a Phase...

2024-06-04 12:51 1599

Fapon Biopharma Announces a Safer Immunotherapy for Cancers

SAN DIEGO, June 3, 2024 /PRNewswire/ -- At Bio International Convention 2024, which is taking place here inSan Diego during June 3-6, Fapon Biopharma, an innovator in developing therapeutic antibodies and fusion proteins, has announced an immunocytokine with modified IL-10M fused to anti-PD-1 ant...

2024-06-04 09:42 1094

RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88

YANTAI, China, June 4, 2024 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-label, multi-center Phase I/II study evaluating RC8...

2024-06-04 09:38 1684

Minghui Pharmaceutical Presents Phase 1/2 Clinical Data of MHB088C (B7-H3 ADC) as Monotherapy for the Treatment of Patients with Recurrent or Metastatic Solid Tumors at the 2024 ASCO Annual Meeting

SHANGHAI, June 3, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage clinical biopharmaceutical company, announced today that the preliminary Phase 1/2 clinical data of MHB088C (B7-H3 ADC) was presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in an ora...

2024-06-03 21:30 5708

Formosa Laboratories Completes the Acquisition of Synchem to Expand North American CDMO Footprint

TAOYUAN, June 3, 2024 /PRNewswire/ -- Formosa Laboratories, Inc., a leading API supplier and CDMO headquartered inTaiwan, has successfully completed its acquisition of SynChem, Inc., a contract research laboratory located in suburban Chicago. SynChem will now operate under the new name SynChem-For...

2024-06-03 13:01 1438
1 ... 40414243444546 ... 320

Week's Top Stories